The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A phase 1 study of OKI-219 reads out imminently.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
The company takes a PD-L1 x VEGF asset into phase 3.
A new phase 3, Manifest-3, will start in April to support US filing.
